L ymphoma cells are attractive targets for gene transfer, because these cells are potentially susceptible to immunotherapeutic strategies. Recently, cytokine gene transfer and expression of immunomodulatory genes in different kinds of tumor cells have been shown to mediate tumor regression and antimetastatic effects in several animal models. For example, many lymphoma entities respond to a treatment with interferon-␣. 1 Therefore, gene transfer of various cytokine genes such as interleukin-2 (IL-2), IL-7, and IL-12 has been envisaged. 2, 3 The use of genes or genetically modified cells for therapeutic benefit is likely to have a significant therapeutic role for patients with B-cell lymphomas in the future. To date, most gene therapy strategies applicable to the therapy of these diseases have not reached the point of clinical study. Adoptive immunotherapy using donor leukocyte infusion to treat aggressive B-cell neoplasms in immunosuppressed patients has, however, shown great promise clinically, and studies of idiotypic vaccination in patients with low grade B-cell neoplasms are also under way. Results from in vitro and animal studies continue to suggest that it may become possible to use the immune system for therapeutic benefit, and many current basic research strategies in the gene therapy of B-cell non-Hodgkin's lymphoma (NHL) are based on immune modulation of T cells or tumor cells themselves. Other major approaches to gene therapy for B-cell malignancies are the introduction of directly toxic or suicide genes into B cells. All of these approaches require efficient and accurate gene transfer as well as correct expression of the gene product within the target cell. 4 Local secretion of cytokines has been achieved in murine tumor models by introducing genes directly into tumor cells. In contrast to systemic application of cytokines, cytokine gene transfer led to suppressed tumor growth and induction of antitumoral immunity in certain models. 5, 6 Studies in our laboratory are aimed at developing an efficient DNA delivery system and efficacious toxic or inhibitory vectors for lymphoma cells. We have analyzed three methods of gene delivery to this cell type. The first was electroporation as a general approach to the introduction of macromolecules into cells. 7 Second, lipidmediated transfection was selected due to its nontoxic nature and its ability to effectively deliver DNA to many cell types in vitro and in vivo. 8 Adenovirus, the third delivery system we examined, is one of the most promising methods currently being evaluated for gene therapy protocols. There are many advantages for the use of recombinant adenovirus for DNA transfer: adenovirus can be grown to high titers, infects nondividing cells, and mediates high levels of foreign gene expression in target cells. 9, 10 We considered the use of cationic liposomes to enhance gene delivery to lymphoma cells by adenoviral vectors. Cationic liposomes can enhance the entry of enveloped viruses into mammalian cells through pathways that in some cases appear independent of specific receptors and adhesion molecules. 11 In cultured vascular smooth muscle cells (SMC), delivery of adenoviral vectors in the presence of cationic liposomes increased vector-encoded transgene expression up to 20-fold. 12 Transfection of lymphoma cells using physical gene transfer methods, including electroporation, has been reported. 13, 14 However, lymphoma cells are resistant to most gene transfer methods, or transfection methods proved to be too toxic or inefficient for these cells. Recently, lymphoid cells have been shown to be resistant to adenovirus-mediated gene transfer. 15, 16 Here, we describe an adenoviral protocol accomplishing highly efficient gene transfer to B-lymphoma cell lines.
MATERIALS AND METHODS

Cell lines
The following cell lines were analyzed: Raji (human Burkitt lymphoma cell line; obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), Braunschweig, Germany), Daudi (human Burkitt lymphoma cell line; obtained from DSMZ), OCI-Ly8-LAM53 (human lymphoma cell line; obtained from R. Levy, Stanford University, Stanford, Calif), Ra-10 (melanoma cell line; obtained from Virchow Klinikum, Berlin, Germany), and HeLa (human cervix carcinoma cell line; obtained from DSMZ). The cell lines were grown in RPMI 1640 with Glutamax (Life Technologies, Berlin, Germany) supplemented with 10% heat-inactivated fetal calf serum (FCS) (PAA, Martinsried, Germany), 50 g/mL streptomycin, and 50 g/mL penicillin (PAA), and were kept in a humid incubator with 5% CO 2 at 37°C. Virus propagation was performed in the Ad5 E1-transformed human embryonic retina cell line 911. 17 This cell line was grown in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies) supplemented with 10% FCS, 50 g/mL streptomycin, and 50 g/mL penicillin.
Primary lymphoma cells
Six NHL patients were included into this study. Four low-grade malignant cases of NHL and two high malignant cases of NHL were investigated. Two patients with hairy cell leukemia (HCL), one patient with chronic B-cell lymphocytic leukemia (B-CLL), one patient with mantle cell lymphoma, another patient with natural killer cell-leukemia, and one patient with angioimmunoblastic lymphoma were studied. Lymphoma cells were isolated from peripheral blood by Ficoll-Paque density centrifugation. Cell surface antigens of different NHL were analyzed for the expression of CD3, CD11c, CD19, Coxsackieadenoviral receptor (CAR), and ␣ v ␤ 3 -and ␣ v ␤ 5 -integrins. The primary cultures were maintained in liquid culture in RPMI 1640 with Glutamax supplemented with 10% heat-inactivated FCS, 50 g/mL streptomycin, and 50 g/mL penicillin at 37°C, 5% CO 2 . Primary cells could be maintained in culture for 10 -12 days.
Cells were transduced with Ad-␤-gal and Ad-GFP virus. We used Ad-GFP instead of Ad-␤-gal for primary cells because it can be easily measured by flow cytometric studies. Transfection of these cells was considered successful if concurrent CD19 expression with green fluorescent protein (GFP) was observed.
Expression plasmid for ␤-galactosidase (␤-gal)
The plasmid pcDNA3.1/HisB/LacZ was obtained from Invitrogen (de Schelp, The Netherlands). It contains a cytomegalovirus (CMV) enhancer-promoter sequence from the immediate early gene of human CMV, the lacZ open reading frame from Escherichia coli, and a simian virus 40 promoter, origin, and polyadenylation signal.
Plasmid preparation
The plasmid used for transfection was prepared with the Qiagen EndoFree plasmid kit (Qiagen, Hilden, Germany). This kit removes Ͼ99% of contaminating endotoxin.
Electroporation of lymphoma cells
Lymphoma cells were transfected by electroporation under various conditions using the electroporation system Easyject Plus from Eurogentec (Seraing, Belgium). In brief, 5 ϫ 10 6 cells were suspended in 500 L of complete RPMI 1640 medium, mixed with 30 g of pcDNA3.1/HisB/LacZ plasmid in a 4-mm electroporation cuvette, and incubated on ice for 10 minutes. After electroporation with a single or double pulse (electrical parameters between 250 V/1650 F and 250 V/2100 F), the cells were transferred into complete RPMI 1640 medium at a density of 1 ϫ 10 6 cells/mL.
Liposomal gene transfer in lymphoma cells
Lymphoma cells were transfected with pcDNA3.1/HisB/LacZ plasmid using various lipofection reagents (Table 1) . Briefly, lymphoma cells were seeded out in 24-well plates at densities of between 0.5 and 5 ϫ 10 5 cells/mL in RPMI 1640 with or without FCS. The lipofection reagents and plasmid DNA were mixed according to the manufacturer's guidelines. After precipitation, the liposome/DNA complexes were carefully added (drop-wise) to the cells. The cells were incubated with these complexes for 2-24 hours at 37°C, 5% CO 2 . At 24 -48 hours posttransfection, the cells were stained for ␤-gal expression.
Adenoviral-mediated gene transfer to lymphoma cells: Preparation of adenovirus and virus infection
The recombinant adenoviral Ad-␤-gal vector (E1-and E3-deleted replication-defective adenovirus type 5) carrying the E. coli lacZ gene encodes ␤-gal under control of the promoter of the Rous sarcoma virus (Ad-␤-gal was provided by Dr. Karsten Brand, 18 Berlin, Germany). Further experiments with primary cultures were performed with the GFP-expressing adenovirus pQB-AdBM5GFP (Quantum Biotechnologies, Montreal, Canada). This adenovirus contains a CMV promoter.
Production of the adenovirus lots was performed as described by Fallaux et al 17 Briefly, near confluent 911 monolayers in 175-cm 2 flasks were infected with ϳ5 plaque-forming units (PFU) of adenovirus/cell in 2 mL of phosphate-buffered saline (PBS) containing 1% horse sera (HS). After 1 hour at room temperature, the inoculum was replaced by fresh medium (DMEM/2% HS). After 48 hours, the nearly completely detached cells were harvested and collected in 1 mL of PBS/1% HS. Virus was isolated by three cycles of flash-freeze thawing. The lysates were cleared by centrifugation at 3000 rpm for 10 minutes. Virus stock was stored in PBS/10% glycerol at Ϫ80°C.
Plaque assays were essentially performed as described by Graham and Prevec. 19 Briefly, adenovirus stocks were serially diluted in 2 mL of DMEM (Life Technologies) containing 2% HS and added to nearly confluent 911 cells in 6-well plates. After 2 hours of incubation at 37°C, 5% CO 2 , the medium was replaced by F-15 minimal essential medium (Life Technologies) containing 1% agarose (Sigma, Deisenhofen, Germany), 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.4), 0.0025% L-glutamine, 5% yeast extract, 8.4% NaHCO 3 , 50 g/mL streptomycin, 50 g/mL penicillin, and 2% HS. The titer of the Ad-␤-gal was 3.5 ϫ 10 9 PFU/mL; the titer of the Ad-GFP was 5 ϫ 10 9 PFU/mL. Adenoviral transfections with non-CsCl-purified Ad-␤-gal/ Ad-GFP of lymphoma cells were carried out in 24-well plates with 5 ϫ 10 5 cells in 50 L of PBS plus 1 mM MgCl 2 /1% HS, at different multiplicities of infection (MOIs) (0 -200). After 2 hours of incubation at 37°C, 5% CO 2 , 1 mL of complete culture medium was added to the cells. Because no visible toxic effect was observed in comparison with the controls (only PBS plus 1 mM MgCl 2 /1% HS), it was not necessary to remove the virus.
Assay for the determination of replication-competent adenovirus
The recombinant adenovirus (Ad-␤-gal/Ad-GFP) stocks were screened for the presence of replication-competent adenovirus by transfection of 1 ϫ 10 8 HeLa cells with 1 ϫ 10 9 PFU of (each) adenovirus batch. During a period of 10 days, the transfected cells were passaged twice and monitored for cytopathogenic effects.
Combined liposomal and adenoviral transfection
Ad-␤-gal was preincubated with Lipofectamine (Life Technologies) at a final concentration of 20 g/mL in 50 L of Opti-minimal essential medium. The virus-lipid mixture was incubated at 37°C for 30 minutes before addition to the lymphoma cells.
Measurement of ␤-gal expression
5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) staining was performed after 24 -72 hours with a ␤-gal staining kit according to the manufacturer's recommendations (Invitrogen). The percentage of cells with blue nuclei was determined by counting cells in randomly selected microscopic fields. At least 400 cells were counted for each experimental condition.
Growth curves after transfection
Cell viability was determined by trypan blue exclusion. PBS (with 1 mM MgCl 2 /1% HS) was used for mock infection. Noninfected and Ad-␤-gal/Ad-GFP-transfected cells were counted every 24 hours up to 14 days postinfection.
Immunofluorescence and flow cytometric studies (31564X; PharMingen, Hamburg, Germany) or unconjugated ␣ v ␤ 5 monoclonal Ab (mAb) (Chemicon International, Temecula, Calif) in a total volume of 100 L for 15 minutes. The mAb RmcB, 14 which recognizes CAR protein, was kindly provided by Dr. R. Finberg (Harvard Medical School, Boston, Mass). Isotype-matched Abs were used as controls. Stained cells were washed with PBS/bovine serum albumin 1% and subsequently analyzed using an Epics XL flow cytometry system (Coulter, Immunotech, Hamburg, Germany). Background staining using irrelevant Abs was Ͻ2%. A total of 10 4 cells were analyzed for each sample.
The green fluorescence of the Ad-GFP transduced cells was assayed using a 530-nm/30-nm bandpass filter after illumination with an argon ion laser tuned at 488 nm (Coulter, Immunotech) . To analyze the percentage of Ad-GFP-transfected primary lymphoma cells, cells were stained with phycoerythrin-conjugated mAbs for CD19 or CD11c (HCL cultures). The double positive populations were determined.
Statistical analysis
An unpaired Student's t test was used to analyze for statistical significance. A P value of Ͻ.05 was considered significant. Data are presented as the mean Ϯ SD of three comparable experiments.
RESULTS
Transfection of lymphoma cells using electroporation
First, Daudi and Raji lymphoma cell lines were transfected using the electroporation technique. Cells were electroporated at various electrical parameters with plasmid pcDNA3.1/HisB/LacZ, which contains ␤-gal as the reporter gene. Transfection efficiency was determined at 24 and 48 hours after electroporation by ␤-gal staining and microscopic analysis. For both cell lines, the transfection efficiency was always Ͻ2% (Fig 1, a and b) . Viability as determined by trypan blue exclusion was not markedly impaired by electroporation (data not shown).
Transfection of lymphoma cells using lipofection Subsequently, we decided to transfect lymphoma cells by lipofection. Various commercial available transfection reagents were examined ( Table 1 ). The transfection efficiency was again determined using the ␤-gal-encoding plasmid pcDNA3.1/HisB/LacZ and quantitating ␤-gal expression at 24 and 48 hours posttransfection. In summary, the transfection rates were Ͻ1% in Daudi and Raji cells with most of the liposomal formulations (Table 1) . However, with Effectene and Lipofectamine transfection, efficiencies of up to 10% in Raji cells could be achieved (Table 1) . At 72 hours posttransfection, no blue cells were detectable (data not shown).
Transfection of lymphoma cells by an adenoviral vector system
With the goal of developing a gene therapy protocol for lymphoma, we were interested in identifying the most effective method of DNA delivery to lymphoma cells. Therefore, we compared the efficiency of lipid-mediated DNA delivery with that achieved by an adenoviral vector system. Various MOIs between 50 and 200 were assayed (Fig 2) . Transfection efficiency was determined using a ␤-gal adenovirus and quantitating ␤-gal expression in three separate experiments at 24, 48, and 72 hours posttransfection. Transfection efficiency was dose-dependent. At an MOI of 200, up to 100% of Daudi cells as well as Raji cells and 70 Ϯ 28% LAM53 cells could be transfected. The maximum transgene expression was observed between 48 and 72 hours after addition of the adenoviral vector (Figs 2 and 3) .
Unselected mononuclear cells from lymphoma patients (n ϭ 6) were included in the present study. At 3 days after transfection with Ad-GFP virus at an MOI of 200, GFP was expressed in 57 Ϯ 20% of the CD19 positive cell population (see Fig 5d) .
The main difference compared with other protocols was the prolonged incubation time with the non-CsClpurified adenovirus for 2 hours in a very small volume (50 L). Furthermore, the viral supernatant was not removed and the cells were not washed after incubation with virus.
Time course of Ad-␤-gal transgene expression Daudi, Raji, and LAM53 cells were transfected with Ad-␤-gal at an MOI of 200. Kinetic analysis of transgene expression was observed for up to 14 days. X-Gal staining showed the maximum of 100% of ␤-gal-expressing Daudi and Raji cells after 72 hours; LAM53 revealed 70 Ϯ 28% positive cells. At 14 days posttransfection, the percentage of transgene-expressing cells decreased to 1-7%. These results indicate that adenovirus-mediated gene expression in lymphoma cells was transient.
Growth curves of adenovirally infected lymphoma cells
Cell counts were determined at 24, 48, and 72 hours posttransfection. After adenoviral transfection with a maximum MOI of 200 and addition of Lipofectamine, cell numbers did not differ significantly from untransfected lymphoma cells (Fig 4) . Using primary cells, the viability of transduced cells and control cells decreased rapidly (Fig 4d) . Primary lymphoma cells could not be maintained in culture for Ͼ10 days.
Combined liposomal and adenoviral transfection of lymphoma cells
It was shown that liposomes significantly enhanced transgene expression from adenoviral vectors delivered to cells deficient in ␣ v -integrins. 12 Here, in accordance with reports of SMC, 12 a 30-minute preincubation with cationic liposomes and virion showed more ␤-gal-expressing lymphoma cells after transfection at lower concentrations of adenovirus in comparison with adenoviral transfection without addition of cationic liposomes. At lower vector concentrations (MOI of 50), liposomes augmented the enhancement of transfection efficiency (Fig 5 and Table 2 ). For example, X-Gal staining of Daudi cells at 72 hours posttransfection revealed 74 Ϯ 28% ␤-gal-expressing cells versus 19 Ϯ 9% without Lipofectamine (Fig 5a) . This increase in transfection rates was dependent upon the presence of liposomes, because preincubation of the virions alone in infection medium for 30 minutes at 37°C had no effect on gene expression. At higher vector concentrations, the degree of liposome enhancement was marginal ( Table 2 , Fig 5) .
Enhancement of transgene GFP expression in primary cells was also observed at an MOI of 50 in combination with Lipofectamine. At 72 hours after transfection with Ad-GFP, which resulted in 28% positive cells, preincubation with Lipofectamine showed 52% GFP-expressing tumor cells (P ϭ .04; Fig 5d) . Transfection with Ad-GFP at an MOI of 200 and addition of liposomes resulted in the highest efficiencies (67% ; Fig 5d) .
Expression of CAR and integrins on the cell surface of lymphoma cells
Adenoviruses enter their target cells via CAR. 20, 21 Viral binding to this receptor is followed by endocytosis, which is mediated by cellular ␣ v -containing integrins, in particular the integrin receptors ␣ v ␤ 3 (CD51/CD61) and ␣ v ␤ 5 . ␣ v ␤ 3 has been demonstrated to be an alternative receptor for adenoviral cell entry. 22 We determined the expression of these receptors on the cell surface of lymphoma cells. The melanoma cell line Ra-10 was used as a positive control for ␣ v ␤ 3 , and the lung cancer cell line A549 was used as positive control for ␣ v ␤ 5 -integrins. It was shown that the levels of integrin ␣ v ␤ 5 may predict the susceptibility to adenovirus-mediated gene transfer in some cell lines. 23 The lymphoma cell lines Daudi, Raji, and LAM53 did not express integrin receptors as determined by immunophenotyping and fluorescenceactivated cell sorter analysis (Table 3) . Expression of CAR was found on the cell surface of Daudi (88 Ϯ 3%) and Raji (69 Ϯ 6%) cells (Fig 6, a and b) . In contrast, the expression of CAR on the surface of LAM53 cells was very low (6 Ϯ 1%) (Fig 6c) .
Expression of CAR and integrins on the surface of the primary cells obtained from patients (n ϭ 6) showed a weak expression of ␣ v ␤ 5 ranging from 2% to 7% but no detectable signals for ␣ v ␤ 3 . CAR expression was Ͻ6 -9% on the cell surface of the different lymphomas (Fig 6d) ; only the HCL population displayed CD19 (95%) and CD11c (95%) on the cell surface and showed a strong expression of CAR (Table 3 and Fig 6e) .
DISCUSSION
Lymphoma cells are being considered as suitable targets for gene therapy. Cytogenetic studies of lymphoma cells have identified mutations and chromosomal aberrations, in particular chromosome translocations affecting the bcl-2, c-myc, and p53 genes. 24 Vectors expressing bcl-2 antisense sequences or cytokine genes have been suggested. [25] [26] [27] [28] Epstein-Barr virus-based vectors can be used for targeted gene transfer to Epstein-Barr virusassociated neoplasms. 29 -31 Targeted disruption of the ␤ 1 -integrin gene in a lymphoma cell line reduced its metastatic capacity. 32 All of these approaches require efficient gene transfer as well as correct expression of the gene product within in target cells. 4 Although adenoviral vectors offer a number of potential advantages over retroviral vectors for immunotherapeutic approaches to lymphoma, 33 previous reports have demonstrated that human lymphoid cells are resistant to adenoviral transduction. 15, 34, 35 However, the ability of adenoviral vectors to mediate gene transfer into nondividing cells and the feasibility to produce high titers make the application of adenoviral vectors attractive for gene delivery. In immunotherapeutic approaches, sustained gene transfer is not essential. Thus, the transient nature of gene expression achieved by adenoviral vectors is acceptable, if not even desirable. 15 Despite their advantages as gene transfer vectors, adenoviral vectors are limited by suboptimal efficiency and by toxicity at high concentrations. 9,36 -38 In this study, we sought to optimize the gene delivery into lymphoma cells as a first step toward a gene therapy approach. We compared the efficiency of electroporation and lipid-and adenoviral-mediated gene transfer into lymphoma cells in vitro. Using established human lymphoma cell lines, we have analyzed various transfection reagents and examined different variables such as lipid/DNA ratio, length of exposure to lipid/DNA complexes, cell density, and culture conditions to determine their effects on the transfection efficiency.
In accordance with the literature, we observed that lymphoma cells are resistant to lipofection and electroporation. 13, 14 In contrast, lymphoma cells could be transfected with our protocol using the adenovirus vector presented here. Other adenoviral transfection protocols showed negative results. Prince et al 15 reported of a transfection efficiency of 14% for B lymphocytes. LacZ or luciferase expression was almost 100 times lower in MOI of 200, and 67% of primary cells could be transfected. This enables the use of a low MOI leading to no major toxic effects to lymphoma cells.
The main difference in our protocol seems to be the persistent presence of non-CsCl-purified adenoviruses in the supernatant of the cells and the prolonged incubation time of 2 hours at 37°C at a high cell density and high viral concentration. Successful adenoviral transduction is dependent upon a series of physical and biological events. The first step is the collision of a virion with a cell. Decreasing the volume-to-surface area ratio decreases the distance between virions and cells and therefore increases the probability of a collision. 39 The initiating event in adenoviral gene delivery is binding of the viral capsid to a cell surface receptor. 21, 40 Viral binding is followed by endocytosis, mediated by cellular ␣ v -containing integrins. [41] [42] [43] [44] [45] [46] Adenoviral gene delivery to specific cell types may be limited by the availability of receptors. In addition, adenoviral gene transfer is related to different expression of cell surface integrins, such as ␣ v ␤ 3 or ␣ v ␤ 5 . The integrins are required for efficient internalization of the adenovirus. 23, 34, [45] [46] [47] We observed low expression levels of integrins on the lymphoma cell surface, which suggests that the adenoviral entry into these cells is mediated by CAR, expressed on the surface of lymphoma cells. The cell line LAM53 expressed only weak levels of CAR, but the transduction efficiency was nearly the same observed in the other cell lines. One likely explanation is that these cells express other groups of integrins that are responsible for virus binding. Another receptor of the knob domain is the ␣2 domain of major histocompatibility complex class I, which is expressed weakly on peripheral blood cells. 48, 49 In contrast, integrin receptors do not seem to play a major role, because most lymphoma cells were negative for CD49 (except Daudi cells, which express ␣ v ␤ 1 in a nonfunctional configuration) and negative for CD51 integrins. 50 Transfection efficiency at a low MOI can be further increased by addition of lipofection to adenoviral gene transfer. 12, 16 It has been shown that cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and ␣ v -integrins. 12, 16 Liposomes enhance transgene expression from adenoviral vectors delivered to cells that are also deficient in ␣ v -containing integrins such as SMC. 12 Similar to our results in lymphoma cells, the magnitude of liposome enhancement of transgene expression was greatest at low concentrations of the virus. Approximately 70% ␤-gal-expressing lymphoma cells and 52% GFP-expressing primary cells were observed at an MOI of 50 after 72 hours. The advantage of this gene delivery technique by adenoviral vectors in combination with liposomes is that less recombinant virus is required. Although addition of liposomes did not improve in vivo adenoviral gene delivery in general, 12 these works have implications to the successful application of gene transfer technology in vitro.
At least three different mechanisms have been proposed for this observation, as discussed by Qiu et al 12 Cationic liposomes form complexes with virions via Lymphoma cell lines were transduced as described in Materials and Methods. At 72 hours post-transfection, cells were harvested and the percentage of positive cells after X-Gal staining for 4 hours was determined. Primary cells were assayed by flow cytometry. The bold data represent significant values (mean Ϯ SEM of three independent experiments). The level of mAb staining on the cell population was indicated by fluorescence intensity: Ϫ, no detectable staining; ϩ/Ϫ, 5 ϫ background; ϩ, 5-10 ϫ background; ϩϩ, 10 -50 ϫ background; ϩϩϩ, 50 -100 ϫ background. electrostatic interactions. Excess positive charges in the liposome-containing complexes would then enhance interactions with the negatively charged cell surfaces. Cellular uptake of the complexes could then occur either through membrane fusion, endocytosis, or enhanced binding to specific cell surface receptors.
The ability to efficiently manipulate gene expression in B lymphocytes by using adenovirus vectors should facilitate the functional characterization of pathways affecting lymphocyte physiology. In conclusion, we present a protocol of adenoviral gene transfer leading to highly efficient gene transfer in B-lymphoma cell lines without major toxicity. This protocol should have an important impact on the use of lymphoma cells in cancer gene therapy protocols.
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